Beone Medicines

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments (bendamustine plus rituximab or high-dose methylprednisolone plus rituximab) in 150 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymp…

This Phase 3 trial compares a new two-drug combination (sonrotoclax plus zanubrutinib) against a standard therapy (venetoclax plus obinutuzumab) in 652 adults with previously untreated chronic lymphocytic leukemia (CLL). The goal is to see which approach better delays disease pro…

This phase 3 trial is testing whether a combination of zanubrutinib (a targeted cancer pill) plus an anti-CD20 antibody works better than the current standard of lenalidomide plus rituximab for people with relapsed or refractory follicular or marginal zone lymphoma. About 780 par…

This study tests whether the drug zanubrutinib can help people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 178 participants will receive either zanubrutinib or the standard drug tacrolimus. The goal is to see if zanubrutinib reduces pr…

This study tests whether adding sonrotoclax to the standard drug zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to see if the…

This early-phase study tests a new drug called BGB-11417 (sonrotoclax) in people with B-cell blood cancers that have come back or not responded to treatment. The goal is to find the safest dose and see how well it works alone or combined with other drugs. About 437 adults will ta…

This study tests whether a new drug combination (zanubrutinib plus rituximab) works better than standard chemotherapy (bendamustine plus rituximab) for people with untreated mantle cell lymphoma who cannot have a stem cell transplant. About 510 participants will be randomly assig…

This phase 2 study tests a new drug called sonrotoclax, either alone or combined with zanubrutinib, in 114 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if the treatment can shrink tumors and control the disease. Participants include those who…